137 related articles for article (PubMed ID: 29925500)
1. Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine.
Manwani R; Sachchithanantham S; Mahmood S; Foard D; Sharpley F; Rezk T; Lane T; Quarta C; Fontana M; Lachmann HJ; Gillmore JD; Whelan C; Hawkins PN; Wechalekar AD
Blood; 2018 Aug; 132(7):761-764. PubMed ID: 29925500
[No Abstract] [Full Text] [Related]
2. Updated analysis of phase 2 study of bendamustine and dexamethasone in patients with relapsed/refractory systemic light chain (AL) amyloidosis.
Lentzsch S; Lagos GG; Comenzo RL; Zonder JA; Pregja S; Osman K; Tsai WY; Landau H; Sanchorawala V
Amyloid; 2019; 26(sup1):113-114. PubMed ID: 31343313
[No Abstract] [Full Text] [Related]
3. Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis.
Milani P; Schönland S; Palladini G; Kimmich C; Basset M; Russo F; Foli A; Perlini S; Bochtler T; Ho AD; Merlini G; Hegenbart U
Amyloid; 2017 Mar; 24(sup1):56-57. PubMed ID: 28434298
[No Abstract] [Full Text] [Related]
4. IgGκ light and heavy chain amyloidosis secondary to a B-cell lymphoproliferative disorder, whole picture on a renal biopsy.
Ville S; Kandel C; Delaunay J; Cantarovich D
Nephrology (Carlton); 2020 May; 25(5):429-430. PubMed ID: 31726478
[No Abstract] [Full Text] [Related]
5. Treatment of AL amyloidosis with bendamustine: a study of 122 patients.
Milani P; Schönland S; Merlini G; Kimmich C; Foli A; Dittrich T; Basset M; Müller-Tidow C; Bochtler T; Palladini G; Hegenbart U
Blood; 2018 Nov; 132(18):1988-1991. PubMed ID: 30108065
[No Abstract] [Full Text] [Related]
6. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Seymour JF; Kipps TJ; Eichhorst B; Hillmen P; D'Rozario J; Assouline S; Owen C; Gerecitano J; Robak T; De la Serna J; Jaeger U; Cartron G; Montillo M; Humerickhouse R; Punnoose EA; Li Y; Boyer M; Humphrey K; Mobasher M; Kater AP
N Engl J Med; 2018 Mar; 378(12):1107-1120. PubMed ID: 29562156
[TBL] [Abstract][Full Text] [Related]
7. Anti Myelin-Associated-Glycoprotein Antibody Peripheral Neuropathy Response to Combination Chemoimmunotherapy With Bendamustine/Rituximab in a Patient With Biclonal IgM κ and IgM λ: Case Report and Review of the Literature.
Gomez A; Hoffman JE
Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):e101-8. PubMed ID: 27245314
[No Abstract] [Full Text] [Related]
8. Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of
Eskelund CW; Albertsson-Lindblad A; Kolstad A; Laurell A; Räty R; Pedersen LB; Geisler CH; Jerkeman M; Grønbæk K
Haematologica; 2018 Nov; 103(11):e541-e543. PubMed ID: 29794145
[No Abstract] [Full Text] [Related]
9. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
[TBL] [Abstract][Full Text] [Related]
10. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
Eichhorst B; Fink AM; Bahlo J; Busch R; Kovacs G; Maurer C; Lange E; Köppler H; Kiehl M; Sökler M; Schlag R; Vehling-Kaiser U; Köchling G; Plöger C; Gregor M; Plesner T; Trneny M; Fischer K; Döhner H; Kneba M; Wendtner CM; Klapper W; Kreuzer KA; Stilgenbauer S; Böttcher S; Hallek M; ;
Lancet Oncol; 2016 Jul; 17(7):928-942. PubMed ID: 27216274
[TBL] [Abstract][Full Text] [Related]
11. Bendamustine and rituximab in elderly patients with low-tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study.
Gyan E; Sonet A; Brice P; Anglaret B; Laribi K; Fruchart C; Tilly H; Araujo C; Soubeyran P; Gonzalez H; Morineau N; Nicolas-Virelizier E; Ghesquières H; Salles B; Bouabdallah R; Orfeuvre H; Fahri J; Couturier O; Xerri L; Feugier P;
Br J Haematol; 2018 Oct; 183(1):76-86. PubMed ID: 30117149
[TBL] [Abstract][Full Text] [Related]
12. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
[TBL] [Abstract][Full Text] [Related]
13. Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis.
Wechalekar AD; Whelan C
Blood Cancer J; 2017 Mar; 7(3):e546. PubMed ID: 28338670
[No Abstract] [Full Text] [Related]
14. Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma.
Hill BT; Nastoupil L; Winter AM; Becnel MR; Cerhan JR; Habermann TM; Link BK; Maurer MJ; Fakhri B; Reddy P; Smith SD; Mukhija D; Jagadeesh D; Desai A; Alderuccio JP; Lossos IS; Mehra P; Portell CA; Goldman ML; Calzada O; Cohen JB; Hussain MJ; Ghosh N; Caimi P; Tiutan T; Martin P; Kodali A; Evens AM; Kahl BS
Br J Haematol; 2019 Feb; 184(4):524-535. PubMed ID: 30575016
[TBL] [Abstract][Full Text] [Related]
15. Long term outcome of patients treated on clinical trials of immunomodulatory agents for the treatment of Immunoglobulin light chain (AL) amyloidosis: A pooled analysis.
Sanchorawala V; Doros G; Shelton AC
Am J Hematol; 2019 Jul; 94(7):E194-E196. PubMed ID: 31020691
[No Abstract] [Full Text] [Related]
16. Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lymphoma: a multicenter phase II study.
Sakai R; Ohmachi K; Sano F; Watanabe R; Takahashi H; Takasaki H; Tanaka M; Hattori Y; Kimura H; Takimoto M; Tachibana T; Tanaka E; Ishii Y; Ishiyama Y; Hagihara M; Miyazaki K; Yamamoto K; Tomita N; Ando K
Ann Hematol; 2019 Sep; 98(9):2131-2138. PubMed ID: 31286196
[TBL] [Abstract][Full Text] [Related]
17. Paraprotein associated syndrome treated successfully with chemotherapy.
Gurung R; Robertson C; Vickers MA
BMJ Case Rep; 2020 Sep; 13(9):. PubMed ID: 32912879
[TBL] [Abstract][Full Text] [Related]
18. Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08.
Hitz F; Zucca E; Pabst T; Fischer N; Cairoli A; Samaras P; Caspar CB; Mach N; Krasniqi F; Schmidt A; Rothermundt C; Enoiu M; Eckhardt K; Berardi Vilei S; Rondeau S; Mey U
Br J Haematol; 2016 Jul; 174(2):255-63. PubMed ID: 27018242
[TBL] [Abstract][Full Text] [Related]
19. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.
Zelenetz AD; Barrientos JC; Brown JR; Coiffier B; Delgado J; Egyed M; Ghia P; Illés Á; Jurczak W; Marlton P; Montillo M; Morschhauser F; Pristupa AS; Robak T; Sharman JP; Simpson D; Smolej L; Tausch E; Adewoye AH; Dreiling LK; Kim Y; Stilgenbauer S; Hillmen P
Lancet Oncol; 2017 Mar; 18(3):297-311. PubMed ID: 28139405
[TBL] [Abstract][Full Text] [Related]
20. Chronic hepatitis E in patients with indolent lymphoma after treatment with rituximab and bendamustine.
Alnuaimi K; Lavolé J; Lascoux-Combes C; Roque Afonso AM; Sogni P; Pol S; Mallet V
Hepatology; 2018 Jun; 67(6):2468-2470. PubMed ID: 29194671
[No Abstract] [Full Text] [Related]
[Next] [New Search]